Kemmerling, R., Alinger, B., Dietze, O., Bosmuller, H. C., Ocker, M., Wolkersdorfer, G. W., . . . Kiesslich, T. (2012).,
Association of stem cell marker expression pattern and survival in human biliary tract cancer., International Journal of Oncology, 41(2), 511-522. doi:10.3892/ijo.2012.1477 [doi]
Frandsen, S. K., Gissel, H., Hojman, P., Tramm, T., Eriksen, J., & Gehl, J. (2012).,
Direct therapeutic applications of calcium electroporation to effectively induce tumor necrosis., Cancer Research, 72(6), 1336-1341. doi:10.1158/0008-5472.CAN-11-3782 [doi]
Garcia-Garcia, C., Ibrahim, Y. H., Serra, V., Calvo, M. T., Guzman, M., Grueso, J., . . . Scaltriti, M. (2012).,
Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy., Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 18(9), 2603-2612. doi:10.1158/1078-0432.CCR-11-2750 [doi]
Knauer, S. K., Unruhe, B., Karczewski, S., Hecht, R., Fetz, V., Bier, C., . . . Stauber, R. H. (2013).,
Functional characterization of novel mutations affecting survivin (BIRC5)-mediated therapy resistance in head and neck cancer patients., Human Mutation, 34(2), 395-404. doi:10.1002/humu.22249 [doi]
Tritten, L., Nwosu, U., Vargas, M., & Keiser, J. (2012).,
In vitro and in vivo efficacy of tribendimidine and its metabolites alone and in combination against the hookworms heligmosomoides bakeri and ancylostoma ceylanicum., Acta Tropica, 122(1), 101-107. doi:10.1016/j.actatropica.2011.12.008 [doi]
Hantel, C., Lewrick, F., Reincke, M., Suss, R., & Beuschlein, F. (2012).,
Liposomal doxorubicin-based treatment in a preclinical model of adrenocortical carcinoma., The Journal of Endocrinology, 213(2), 155-161. doi:10.1530/JOE-11-0427 [doi]
Hantel, C., Jung, S., Mussack, T., Reincke, M., & Beuschlein, F. (2014).,
Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model., Endocrine-Related Cancer, 21(3), 383-394. doi:10.1530/ERC-13-0439 [doi]
Pool, S. E., Bison, S., Koelewijn, S. J., van der Graaf, L. M., Melis, M., Krenning, E. P., & de Jong, M. (2013).,
mTOR inhibitor RAD001 promotes metastasis in a rat model of pancreatic neuroendocrine cancer., Cancer Research, 73(1), 12-18. doi:10.1158/0008-5472.CAN-11-2089 [doi]
Wang, C. F., Sarparanta, M. P., Makila, E. M., Hyvonen, M. L., Laakkonen, P. M., Salonen, J. J., . . . Santos, H. A. (2015).,
Multifunctional porous silicon nanoparticles for cancer theranostics., Biomaterials, 48, 108-118. doi:10.1016/j.biomaterials.2015.01.008 [doi]
Ibrahim, Y. H., Garcia-Garcia, C., Serra, V., He, L., Torres-Lockhart, K., Prat, A., . . . Baselga, J. (2012).,
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition., Cancer Discovery, 2(11), 1036-1047. doi:10.1158/2159-8290.CD-11-0348 [doi]
Serra, V., Eichhorn, P. J., Garcia-Garcia, C., Ibrahim, Y. H., Prudkin, L., Sanchez, G., . . . Baselga, J. (2013).,
RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer., The Journal of Clinical Investigation, 123(6), 2551-2563. doi:10.1172/JCI66343 [doi]
Boven, E., Schipper, H., Erkelens, C. A., Hatty, S. A., & Pinedo, H. M. (1993).,
The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer., British Journal of Cancer, 68(1), 52-56.